Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2024-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2024
2024-05-14 English
Regulatory Filings 2024
Regulatory Filings
2024-04-30 English
ARS
Annual Report
2024-04-26 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement related to the Annual Meeting of Stockholders. It includes details about the meeting date, voting instructions, director nominations, and proposals to be voted on, such as the ratification of the independent auditor. The document is titled 'Definitive Additional Materials' and is clearly proxy solicitation material. It does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Earnings Release. It is not a report publication announcement since it contains substantive proxy meeting information. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains detailed proxy information, not just a notice or announcement, so it is not RPA or RNS.
2024-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-26 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a formal communication related to a securities registration process, specifically an acceleration request under Rule 461 of the Securities Act of 1933. The document does not contain financial data, report content, or detailed disclosures but is rather an administrative request related to a capital markets filing. Given its nature as a regulatory communication about a registration statement effectiveness, it fits best under Capital/Financing Update (CAP). The document length is short and it is not a report itself but a procedural filing related to capital raising.
2024-04-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.